Romidepsin, CC-486 (5-azacitidine), Dexamethasone, and Lenalidomide (RAdR) for Relapsed/Refractory T-cell Malignancies

计划入组 26 人 · 首次发布于 2020 年 6 月 25 日

Radiosurgery Dose Reduction for Brain Metastases on Immunotherapy (RADREMI): A Prospective Pilot Study

计划入组 21 人 · 首次发布于 2019 年 8 月 7 日

Radiofrequency Before to Surgical Removal of a Recalcitrant Morton´s Neuroma

计划入组 34 人 · 首次发布于 2022 年 9 月 22 日

Radretumab

131I-radretumab

LADR-10

BIO-RAD

France

BADR UNIVERSITY IN CAIRO

Egypt

RADY CHILDREN'S HOSPITAL-SAN DIEGO

United States

Lantern Pharma Highlights AI-Driven Oncology Drug Development in Upcoming Webinars

Lantern Pharma Secures European Patent for AI-Developed Cancer Therapy LP-284

AI-Guided Drug LP-284 Achieves Complete Response in Treatment-Resistant Lymphoma Patient